Cannabigerol Treatment Shows Antiproliferative Activity and Causes Apoptosis of Human Colorectal Cancer Cells
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: To determine growth inhibitory and anti-cancer effects of Cannabigerol (CBG) in human colorectal cancer cells. Methods: Anti-proliferative effect of CBG was examined using MTT assay and two colorectal cancer cells (SW480 and LoVo cells). Cell death ratio was analyzed using Annexin V/ PI staining experiment. Cell cycle distribution was analyzed using flow cytometry. We also performed western blot analysis on apoptotic marker proteins. Results: CBG showed growth inhibitory effect in colorectal cancer cells using MTT assay. IC50 concentration of CBG was 34.89 μM in SW480 cells and 23.51 μM in LoVo cells. Annexin V/PI staining showed that CBG treatment increased apoptotic cells from 4.8% to 31.7% in SW480 cells and from 7.7% to 33.9% in LoVo cells. Flow cytometry confirmed that CBG increased sub G1 population via G1 arrest in both SW480 and LoVo cells. Western blot analysis showed that CBG increased expression levels of cell death-related proteins such as cleaved PARP-1, cleaved caspase 9, p53, and caspase 3. Conclusion: CBG treatment shows antiproliferative activity and causes apoptosis of colorectal cancer cells, suggesting that CBG is applicable as a promising anticancer drug.
Abstract
Objectives: To determine growth inhibitory and anti-cancer effects of Cannabigerol (CBG) in human colorectal cancer cells. Methods: Anti-proliferative effect of CBG was examined using MTT assay and two colorectal cancer cells (SW480 and LoVo cells). Cell death ratio was analyzed using Annexin V/ PI staining experiment. Cell cycle distribution was analyzed using flow cytometry. We also performed western blot analysis on apoptotic marker proteins. Results: CBG showed growth inhibitory effect in colorectal cancer cells using MTT assay. IC50 concentration of CBG was 34.89 μM in SW480 cells and 23.51 μM in LoVo cells. Annexin V/PI staining showed that CBG treatment increased apoptotic cells from 4.8% to 31.7% in SW480 cells and from 7.7% to 33.9% in LoVo cells. Flow cytometry confirmed that CBG increased sub G1 population via G1 arrest in both SW480 and LoVo cells. Western blot analysis showed that CBG increased expression levels of cell death-related proteins such as cleaved PARP-1, cleaved caspase 9, p53, and caspase 3. Conclusion: CBG treatment shows antiproliferative activity and causes apoptosis of colorectal cancer cells, suggesting that CBG is applicable as a promising anticancer drug.
참고문헌 (35)
- Sawicki T, "A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis", Cancers(Basel), 13(9), pp.2025~ (2021)
- Kumar A, "Current and emerging therapeutic approaches for colorectal cancer : a comprehensive review", World J Gastrointest Surg, 15(4), pp.495~519 (2023)
- Tirendi S, "Colorectal cancer and therapy response : a focus on the main mechanisms involved", Front Oncol, 13, pp.1208140~ (2023)
- Hossain MS, "Colorectal cancer : a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies", Cancers(Basel), 14(7), pp.1732~ (2022)
- Zeineddine FA, "Survival improvement for patients with metastatic colorectal cancer over twenty years", NPJ Precis Oncol, 7(1), pp.16~ (2023)
- Van Cutsem E, "Oral capecitabine vs intravenous 5-fluorouracil and leucovorin : integrated efficacy data and novel analyses from two large, randomised, phase III trials", Br J Cancer, 90(6), pp.1190~1197 (2004)
- Zhang N, "5-Fluorouracil : mechanisms of resistance and reversal strategies", Molecules, 13(8), pp.1551~1569 (2008)
- Xie YH, "Comprehensive review of targeted therapy for colorectal cancer", Signal Transduct Target Ther, 5(1), pp.22~ (2020)
- Gülck T, "Phytocannabinoids : origins and biosynthesis", Trends Plant Sci, 25(10), pp.985~1004 (2020)
- Stone NL, "A systematic review of minor phytocannabinoids with promising neuroprotective potential", Br J Pharmacol, 177(19), pp.4330~4352 (2020)
- Anderson LL, "Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy", Br J Pharmacol, 178(24), pp.4826~4841 (2021)
- Tahir MN, "The biosynthesis of the cannabinoids", J Cannabis Res, 3(1), pp.7~ (2021)
- Kim AL, "Profiling cannabinoid contents and expression levels of corresponding biosynthetic genes in commercial Cannabis(Cannabis sativa L. )cultivars", Plants(Basel), 11(22), pp.3088~ (2022)
- Jastrząb A, "The origin and biomedical relevance of cannabigerol", Int J Mol Sci, 23(14), pp.7929~ (2022)
- Filipiuc LE, "Major Phytocannabinoids and their related compounds : should we only search for drugs that act on cannabinoid receptors?", Pharmaceutics, 13(11), pp.1823~ (2021)
- di Giacomo V, "Antioxidant and neuroprotective effects induced by cannabidiol and cannabigerol in rat CTX-TNA2 astrocytes and isolated cortexes", Int J Mol Sci, 21(10), pp.3575~ (2020)
- Gugliandolo A, "In vitro model of neuroinflammation : efficacy of cannabigerol, a non-psychoactive cannabinoid", Int J Mol Sci, 19(7), pp.1992~ (2018)
- Appendino G, "Antibacterial cannabinoids from Cannabis sativa : a structure-activity study", J Nat Prod, 71(8), pp.1427~1430 (2008)
- Lah TT, "Cannabigerol is a potential therapeutic agent in a novel combined therapy for glioblastoma", Cells, 10(2), pp.340~ (2021)
- Viereckl MJ, "Cannabidiol and cannabigerol inhibit cholangiocarcinoma growth in vitro via divergent cell death pathways", Biomolecules, 12(6), pp.854~ (2022)
- Wyrobnik I, "Decreased melanoma CSF-1 secretion by Cannabigerol treatment reprograms regulatory myeloid cells and reduces tumor progression", Oncoimmunology, 12(1), pp.2219164~ (2023)
- Schilling S, "Cannabis sativa", Curr Biol, 30(1), pp.R8~R9 (2020)
- Grunfeld Y, "Psychopharmacological activity of the active constituents of hashish and some related cannabinoids", Psychopharmacologia, 14(3), pp.200~210 (1969)
- Nachnani R, "The pharmacological case for cannabigerol", J Pharmacol Exp Ther, 376(2), pp.204~212 (2021)
- Zagožen M, "Cannabigerol and cannabichromene in Cannabis sativa L", Acta Pharm, 71(3), pp.355~364 (2020)
- Echeverry C, "A comparative in vitro study of the neuroprotective effect induced by cannabidiol, cannabigerol, and their respective acid forms : relevance of the 5-HT1A receptors", Neurotox Res, 39(2), pp.335~348 (2021)
- Park YJ, "Cannabidiol regulates PPARγ-dependent vesicle formation as well as cell death in A549 human lung cancer cells", Pharmaceuticals(Basel), 15(7), pp.836~ (2022)
- Kwon IS, "Metallothionein family proteins as regulators of zinc ions synergistically enhance the anticancer effect of cannabidiol in human colorectal cancer cells", Int J Mol Sci, 24(23), pp.16621~ (2023)
- Sharma K, "Cytotoxic autophagy in cancer therapy", Int J Mol Sci, 15(6), pp.10034~10051 (2014)
- Ramirez A, "Cannabidiol activates PINK1-Parkin-dependent mitophagy and mitochondrialderived vesicles", Eur J Cell Biol, 101(1), pp.151185~ (2022)
- De Petrocellis L, "Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo : pro-apoptotic effects and underlying mechanisms", Br J Pharmacol, 168(1), pp.79~102 (2013)
- Yüksel B, "Cannabinoid compounds in combination with curcumin and piperine display an anti-tumorigenic effect against colon cancer cells", Front Pharmacol, 14, pp.1145666~ (2023)
- Łuczaj W, "Differences in the phospholipid profile of melanocytes and melanoma cells irradiated with UVA and treated with cannabigerol and cannabidiol", Sci Rep, 13(1), pp.16121~ (2023)
- Mahmoud AM, "Cannabidiol alters mitochondrial bioenergetics via VDAC1 and triggers cell death in hormonerefractory prostate cancer", Pharmacol Res, 189, pp.106683~ (2023)
- Shalev N, "Phytocannabinoid compositions from cannabis act synergistically with PARP1 inhibitor against ovarian cancer cells in vitro and affect the Wnt signaling pathway", Molecules, 27(21), pp.7523~ (2022)